title: Monoclonal antibodies as a strategy for pulmonary diseases.
abstract: Monoclonal antibodies have been used successfully to elucidate the roles of putative mediators of pulmonary disease. In particular, clinical trials with monoclonal antibodies directed against interleukin-5, IgE or CD4 yielded results that were critical in dissecting the pathophysiology of asthma; but, more importantly, fundamental changes in the discovery, manufacture and safety of monoclonal antibodies have reinforced the enormous potential of these agents in treating pulmonary diseases. An unprecedented number of monoclonal antibodies are in development for a variety of acute and chronic conditions. Moreover, whereas only two monoclonal antibodies had received regulatory approval from the United States Food and Drug Administration between 1986 and 1997, seven more have received approval since then. Indeed, monoclonal antibody therapy has come of age.
authors.affiliation: Centocor Inc., Malvern, PA 19355-1307, USA. torphyt@centocor.com
authors.forename: T J
authors.initials: TJ
authors.lastname: Torphy
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: D E
authors.initials: DE
authors.lastname: Griswold
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal